Two recent studies suggest there is no significant benefit of early biologics over standard step-up care with methotrexate2,3, but these did not ...

We report 5-year safety, efficacy and radiographic outcomes of sarilumab from NCT01061736 and the open-label extension (EXTEND; NCT01146652), in which patients received sarilumab 200 mg every 2 weeks ...

Copyright: © 2019 Elsevier Ltd. All rights reserved.

The FDA has expanded the interchangeable designation for Yuflyma (adalimumab-aaty), a biosimilar to Humira, to include all presentations.

Read more here. While the usual suspects in affordable fashion are always churning out options, true fashion insiders know that some of the best pieces can actually be found at smaller, local labels.

Objectives To investigate efficacy and safety of the Janus kinase-1 inhibitor filgotinib in patients with active rheumatoid arthritis (RA) with limited or no prior methotrexate (MTX) exposure. Methods ...

Background Methotrexate is known to cause folate deficiency which can be manifested early on as macrocytosis in a complete blood count. Some clinical manifestations of folate deficiency such as ...